Progyny (NASDAQ:PGNY – Get Free Report) had its price target hoisted by investment analysts at Citizens Jmp from $33.00 to $38.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp‘s target price would suggest a potential upside of 10.95% from the company’s current price.
Other analysts also recently issued reports about the company. Canaccord Genuity Group set a $35.00 price target on Progyny in a report on Friday, August 7th. KeyCorp increased their price objective on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Wall Street Zen lowered Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. Finally, Truist Financial boosted their target price on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Ten investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.92.
Check Out Our Latest Report on PGNY
Progyny Stock Performance
PGNY stock opened at $34.25 on Thursday. The company’s 50 day moving average price is $27.11 and its 200 day moving average price is $24.49. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 2.01 and a beta of 0.97. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $34.90.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. The company had revenue of $341.25 million during the quarter, compared to the consensus estimate of $340.76 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share. Equities analysts forecast that Progyny will post 1.25 EPS for the current fiscal year.
Insider Buying and Selling at Progyny
In other Progyny news, COO Melissa Cummings sold 1,879 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at approximately $1,861,888. The trade was a 2.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total transaction of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at approximately $1,978,797.60. This trade represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 17,282 shares of company stock worth $475,790. Insiders own 9.90% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in PGNY. Public Employees Retirement System of Ohio acquired a new stake in shares of Progyny during the 2nd quarter valued at $29,000. Nykredit A S acquired a new position in shares of Progyny in the 2nd quarter worth $38,000. IFP Advisors Inc grew its holdings in shares of Progyny by 376.0% in the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in shares of Progyny in the 2nd quarter worth $65,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Progyny during the second quarter worth $74,000. Institutional investors and hedge funds own 94.93% of the company’s stock.
Key Stories Impacting Progyny
Here are the key news stories impacting Progyny this week:
- Positive Sentiment: Progyny reported Q3 earnings of $0.52 per share, above analyst estimates, on revenue of $341.25 million, slightly ahead of expectations and up 8.9% year over year. The company also characterized the quarter as record-setting. Progyny Q3 results
- Positive Sentiment: The company raised its full-year 2026 earnings guidance and issued fourth-quarter guidance. A higher forecast can signal improving expectations for profitability. 2026 earnings guidance
- Positive Sentiment: Citizens raised its price target to $38 following the guidance increase, while Cantor Fitzgerald lifted its target from $31 to $35 and maintained an Overweight rating. Citizens price-target update
- Neutral Sentiment: A Q3 review highlighted new client wins and margin expansion, but described the market response as cautious—suggesting investors may want further evidence that growth and profitability will persist. Q3 business and market review
Progyny Company Profile
Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.
Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.
Progyny primarily serves self-insured employers and their employees in the United States.
Featured Articles
- Five stocks we like better than Progyny
- Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
- How Much of Tesla’s Robotaxi Future Is Already Priced In?
- 3 AI Infrastructure Plays Beyond Chipmakers
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
